Ophthalmologists link immunotherapy with a serious eye condition

May 7, 2018, University of Michigan
Immunotherapy cancer drugs can cause a potentially vision-robbing side effect. In a new report, Dr. Hakan Demirci, ocular oncologist at Kellogg Eye Center, discusses the risks and what oncologists should know. Credit: University of Michigan Kellogg Eye Center

New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

But the treatments, designed to unleash the immune system to attack cancer, can also spur an assault on healthy organs, including the eye.

The cases of three recent , published by University of Michigan Kellogg Eye Center in JAMA Ophthalmology, highlight the issue. Patients receiving immune checkpoint inhibitors developed uveal effusions and eye inflammation that affected their vision.

Although it is rare, knowledge of this risk is important both for the ophthalmologists who treat it and for the oncologists prescribing the anti-cancer treatment, say Michigan Medicine researchers.

With certain inhibitor drugs, the anti-PD-1 (programmed cell death protein-1) and anti-PD-L1 (programmed cell death ligand-1) monoclonal antibody immune checkpoint inhibitors block the interaction between PD-1 receptors on T cells and their counterpart proteins, PD-L1. This blockage allows the T cells in the immune system to do their job: attack and kill the cancer tumor cells.

"In our three patients who had been receiving these immune checkpoint inhibitors, we noticed large uveal effusions. In addition, there was anterior chamber inflammation in two of our patients," says Hakan Demirci, M.D., the Richard N. and Marilyn K. Witham Professor at the University of Michigan Kellogg Eye Center.

All three patients were receiving an anti-PD-1 or anti-PD-L1 antibody immune checkpoint inhibitor drug: atezolizumab, nivolumab or pembrolizumab.

On development of uveal effusions, Merina Thomas, M.D., a senior vitreoretinal surgery fellow at Kellogg says: "It happened quickly, between one and three months after the patients had received at least two infusions of the immune checkpoint inhibitors. That raised our suspicion."

There's no treatment for the side effects of the immune checkpoint inhibitors other than stopping the medication. "We asked each patient's oncologist if the patient's immune checkpoint inhibitor could be discontinued," says Thomas.

"But not all patients can stop the therapy, because they have widespread, life-threatening cancer," adds Demirci.

In two of the three patients, six weeks to three months after stopping the medication, the uveal effusions had improved and the affected eye looked normal. The third patient with a uveal effusion continued with the immunotherapy for his melanoma, but he died four months later.

Immune response in the eye

In the wall of the normal eye, there are three layers with no fluid among them. But inflammation in the eye can cause the layers to swell and fluid to accumulate between the layers.

Uveal effusions can occur when patients have eye injuries or operations, receive certain drugs, or for unknown causes. When the uveal effusion involves the fovea, where eyesight is the sharpest, it affects the vision.

In a previous review of 576 patients treated with nivolumab, 71 percent had side effects such as fatigue, itching and problems with the gastrointestinal or endocrine systems. Another study noted that uveitis and dry eye were the only ocular toxicities in patients taking PD-1/PD-L1 inhibitors, with the incidence of uveitis ranging from 0.3 to 0.6 percent, and no specifics regarding the pattern or management of the uveitis.

But the Kellogg experts say it's important for oncologists to refer patients with eye problems to an ophthalmologist, and it's equally important for ophthalmologists who see patients with uveitis or uveal effusion to ask them questions about the medications they may be receiving.

More than other organs in the body, the eye is known as an immune-privileged site. The normal immune response to antigens is absent. This means corneal transplants are very successful because the antigens from the grafts seldom produce inflammation in the eye. High levels of PD-L1 in ocular tissues may play a role in the eye's immune privilege. Thus, blockade of the regulatory T cells might have played a role in the toxicity in these patients.

"The immune system is tricky. It can help fight cancer cells but can also start fighting the body itself and cause side effects such as the uveal effusions in these patients," says Thomas.

As the use of immunotherapy becomes more widespread, researchers plan to observe whether more patients are experiencing similar side effects.

Explore further: Cancer immunotherapy found safe in patients with rheumatologic diseases

More information: Merina Thomas et al, Uveal Effusion After Immune Checkpoint Inhibitor Therapy, JAMA Ophthalmology (2018). DOI: 10.1001/jamaophthalmol.2018.0920

Related Stories

Cancer immunotherapy found safe in patients with rheumatologic diseases

January 24, 2018
In the largest single-center study of patients with rheumatologic diseases who were prescribed modern cancer immunotherapy with what are called immune checkpoint inhibitors, only a minority of patients experienced a flare ...

The 'immuno revolution': Turning up the heat on resistant tumors

April 9, 2018
A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don't respond to the newer cancer immunotherapies.

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Could viruses take cancer immunotherapy to the next level?

January 3, 2018
Immunotherapy, which helps the body's immune system attack cancer, has revolutionized treatment for cancers such as melanoma and leukemia. However, many other kinds of cancer remain resistant. A new study led by researchers ...

Novel compound restores immune response in patients with melanoma

December 8, 2017
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

Cancers evade immunotherapy by 'discarding the evidence' of tumor-specific mutations

January 5, 2017
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination ...

Recommended for you

Scientists combine technologies to view the retina in unprecedented detail

November 14, 2018
By combining two imaging modalities—adaptive optics and angiography—investigators at the National Eye Institute (NEI) can see live neurons, epithelial cells, and blood vessels deep in the eye's light-sensing retina. Resolving ...

Eyepatch with dissolvable needles used to treat eye disease

November 12, 2018
A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases. In their paper published in the journal Nature Communications, the ...

Calcifications in the eye increase risk for progression to advanced AMD by more than six times

November 8, 2018
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD). Experts from Queen's University Belfast, working in partnership with the University of Alabama of Birmingham ...

Traditional glaucoma test can miss severity of disease

November 8, 2018
The most common tests for glaucoma can underestimate the severity of the condition by not detecting the presence of central vision loss, according to a new Columbia University study.

New contact lens to treat eye injuries

November 5, 2018
A new therapeutic contact lens that acts as a bandage for eye surface injuries being developed by QUT researchers could soon fast track the healing of previously difficult to treat corneal wounds.

New study offers hope for patients suffering from a rare form of blindness

November 1, 2018
A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.